Heterobifunctional protein degraders, such as PROteolysis TArgeting Chimera (PROTAC)
protein degraders, constitute a novel therapeutic modality that harnesses the cell's natural …

Skin cancer has emerged as the fifth most commonly reported cancer in the world, causing a
burden on global health and the economy. The enormously rising environmental changes …

Ferroptosis is an iron-dependent form of regulated cell death that is triggered by the toxic
build-up of lipid peroxides on cellular membranes. In recent years, ferroptosis has garnered …

Despite being the most frequently altered oncogenic protein in solid tumours, KRAS has
historically been considered 'undruggable'owing to a lack of pharmacologically targetable …

Cancer is the leading cause of death worldwide, and its treatment and outcomes have been
dramatically revolutionised by targeted therapies. As the most frequently mutated oncogene …

Proteolysis targeting chimeras (PROTACs) technology is a novel and promising therapeutic
strategy using small molecules to induce ubiquitin-dependent degradation of proteins. It has …

KRASG12D, the most common oncogenic KRAS mutation, is a promising target for the
treatment of solid tumors. However, when compared to KRASG12C, selective inhibition of …

The cystine/glutamate antiporter SLC7A11 (also commonly known as xCT) functions to
import cystine for glutathione biosynthesis and antioxidant defense and is overexpressed in …

Driver mutations promote initiation and progression of cancer. Pharmacological treatment
can inhibit the action of the mutant protein; however, drug resistance almost invariably …

Pancreatic cancer is an increasingly common cause of cancer mortality with a tight
correspondence between disease mortality and incidence. Furthermore, it is usually …